Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3586-3592

  Miyakoshi, Shigesaburo ^a   Yuji, Koichiro ^a   Kami, Masahiro ^b   Kusumi, Eiji ^a   Kishi, Yukiko ^b   Kobayashi, Kazuhiko ^b   Murashige, Naoko ^b   Hamaki, Tamae ^b   Kim, Sung Won ^b   Ueyama, Jun Ichi ^a   Mori, Shin Ichiro ^b   Morinaga, Shin Ichi ^a   Muto, Yoshitomo ^a   Masuo, Shigeru ^c   Kanemaru, Mineo ^d   Hayashi, Tatsuyuki ^e   Takaue, Yoichi ^b   Taniguchi, Shuichi ^a  

^a TORANOMON HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c JR Tokyo General Hospital   (Japan)

^d Higashijyujyo Hospital   (Japan)

^e TOKYO METROPOLITAN POLICE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; FLUDARABINE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CANCER SURVIVAL; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DIARRHEA; FEMALE; FEVER; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; JAPAN; LYMPHOMA; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; RASH; UMBILICAL CORD BLOOD;

ADULT; AGED; BLOOD PLATELETS; CYCLOSPORINE; FEASIBILITY STUDIES; FEMALE; FETAL BLOOD; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEUTROPHILS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE;

EID: 2542599392     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0754     Document Type: Article

References (35)

1. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
2. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562-8.
3. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-6.
4. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
5. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-8.
6. Blaise DP, Bay JO, Faucher C, et al. Reduced intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004;103:435-41.
7. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997;337:373-81.
8. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998;339:1565-77.
9. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001;344:1815-22.
10. Gardiner CM, Meara AO, Reen DJ. Differential cytotoxicity of cord blood and bone marrow-derived natural killer cells. Blood 1998;91:207-13.
11. Rizzieri DA, Long GD, Vredenburgh JJ, et al. Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood 2001;98:3486-8.
12. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611-8.
13. Kodera Y, Morishima Y, Kato S, et al. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia. Bone Marrow Transplant 1999;24:995-1003.
14. Nishihira H, Kato K, Isoyama K, et al. The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis. Br J Haematol 2003;120:516-22.
15. Kanda Y, Mineishi S, Saito T, et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;28:689-92.
16. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
17. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997;25: 551-73.
18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15: 825-8.
19. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-9.
20. Thiede C, Florek M, Bornhauser M, et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999;23: 1055-60.
21. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced intensity conditioning. Blood. 2003;102:1915-9.
22. Deeg HJ, Amylon ID, Harris RE, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001;7: 208-15.
23. Laughlin MJ, Rizzieri DA, Smith CA, et al. Hematologic engraftment and reconstitution of immune function post unrelated placental cord blood transplant in an adult with acute lymphocytic leukemia. Leuk Res 1998;22:215-9.
24. Gluckman E. Hematopoietic stem-cell transplants using umbilical-cord blood. N Engl J Med 2001;344:1860-1.
25. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol 1988;6:1768-82.
26. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001;97:2962-71.
27. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-62.
28. Nakai K, Mineishi S, Kami M, et al. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation 2003;75:2135-43.
29. Lansdorp PM, Dragowska W, Mayani H. Ontogeny-related changes in proliferative potential of human hematopoietic cells. J Exp Med 1993;178:787-91.
30. Roncarolo MG. Immuno responses of cord blood cells. Bone Marrow Transplant. 1998;22 Suppl 1:S55.
31. Roncarolo MG, Bigler M, Martino S, Ciuti E, Tovo PA, Wagner J. Immune functions of cord blood cells before and after transplantation. J Hematother 1996;5:157-60.
32. Ge Q, Hu H, Eisen HN, Chen J. Naive to memory T-cell differentiation during homeostasis-driven proliferation. Microbes Infect 2002; 4:555-8.
33. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 2000;192:549-56.
34. Hall JM, Lingenfelter P, Adams SL, Lasser D, Hansen JA, Bean MA. Detection of maternal cells in human umbilical cord blood using fluorescence in situ hybridization. Blood 1995;86:2829-32.
35. Sashihara J, Tanaka-Taya K, Tanaka S, et al. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients. Blood 2002;100:2005-11.